Literature DB >> 212612

Mechanism of transfection of chicken embryo fibroblasts by Rous sarcoma virus DNA.

G M Cooper, S Okenquist.   

Abstract

The mechanism of transfection by Rous sarcoma virus DNA was investigated by assaying DNA-mediated transformation under conditions which restricted secondary virus infection. Chicken embryo fibroblasts which were genetically resistant to virus infection as a result of the absence of receptors for virus penetration were also resistant to transformation by integrated or unintegrated Rous sarcoma virus DNA. In addition, DNA of replication-defective Bryan hightiter Rous sarcoma virus was noninfectious, and transformation by DNA of a temperature-sensitive DNA polymerase mutant was temperature sensitive. These results indicated that secondary virus infection was necessary for transformation by Rous sarcoma virus DNA. Since transformation was assayed by colony formation in soft agar, as well as by focus formation, the requirement for secondary virus infection was not an artifact of potential difficulty in detection of foci formed by division of single transformed cells. Therefore, it appeared that donor DNA did not stably transform recipient cells by direct integration. Instead, the results were consistent with the hypothesis that transfection of chicken embryo fibroblasts by Rous sarcoma virus DNA proceeded by transcription of donor DNA, formation of extracellular progeny virus, and secondary virus infection of sensitive cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 212612      PMCID: PMC354246     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

Review 1.  Biological activity of tumor virus DNA.

Authors:  F L Graham
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

2.  Covalently closed circular DNA of avian sarcoma virus: purification from nuclei of infected quail tumor cells and measurement by electron microscopy and gel electrophoresis.

Authors:  R V Guntaka; O C Richards; P R Shank; H J Kung; N Davidson
Journal:  J Mol Biol       Date:  1976-09-15       Impact factor: 5.469

3.  Virus-specific DNA in the cytoplasm of avian sarcoma virus-infected cells is a precursor to covalently closed circular viral DNA in the nucleus.

Authors:  P R Shank; H E Varmus
Journal:  J Virol       Date:  1978-01       Impact factor: 5.103

4.  Subgenomic, cellular Rous sarcoma virus RNAs contain oligonucleotides from the 3' half and the 5' terminus of virion RNA.

Authors:  P Mellon; P H Duesberg
Journal:  Nature       Date:  1977-12-15       Impact factor: 49.962

5.  The size and genetic composition of virus-specific RNAs in the cytoplasm of cells producing avian sarcoma-leukosis viruses.

Authors:  S R Weiss; H E Varmus; J M Bishop
Journal:  Cell       Date:  1977-12       Impact factor: 41.582

6.  Helper-independent transformation by unintegrated Harvey sarcoma virus DNA.

Authors:  D R Lowy; E Rands; E M Scolnick
Journal:  J Virol       Date:  1978-05       Impact factor: 5.103

7.  Electrophoresis of DNA in agarose gels. Optimizing separations of conformational isomers of double- and single-stranded DNAs.

Authors:  P H Johnson; L I Grossman
Journal:  Biochemistry       Date:  1977-09-20       Impact factor: 3.162

8.  Formation and structure of infectious DNA of spleen necrosis virus.

Authors:  E Fritsch; H M Temin
Journal:  J Virol       Date:  1977-01       Impact factor: 5.103

9.  A joint produce of the genes gag and pol of avian sarcoma virus: a possible precursor of reverse transcriptase.

Authors:  H Oppermann; J M Bishop; H E Varmus; L Levintow
Journal:  Cell       Date:  1977-12       Impact factor: 41.582

10.  Assay of noninfectious fragments of DNA of avian leukosis virus-infected cells by marker rescue.

Authors:  G M Cooper; S B Castellot
Journal:  J Virol       Date:  1977-05       Impact factor: 5.103

View more
  31 in total

1.  Development of avian sarcoma and leukosis virus-based vector-packaging cell lines.

Authors:  A W Stoker; M J Bissell
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Rous sarcoma virus nucleic acid-binding protein p12 is necessary for viral 70S RNA dimer formation and packaging.

Authors:  C Méric; P F Spahr
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

3.  Physical map of biologically active Harvey sarcoma virus unintegrated linear DNA.

Authors:  M P Goldfarb; R A Weinberg
Journal:  J Virol       Date:  1979-10       Impact factor: 5.103

4.  Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells.

Authors:  C R Erdie; J W Wills
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

5.  Multiple regions in the Rous sarcoma virus src gene intron act in cis to affect the accumulation of unspliced RNA.

Authors:  C M Stoltzfus; S J Fogarty
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

6.  Efficient transformation by Prague A Rous sarcoma virus plasmid DNA requires the presence of cis-acting regions within the gag gene.

Authors:  C M Stoltzfus; L J Chang; T P Cripe; L P Turek
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

7.  Bacterial beta-galactosidase as a marker of Rous sarcoma virus gene expression and replication.

Authors:  P A Norton; J M Coffin
Journal:  Mol Cell Biol       Date:  1985-02       Impact factor: 4.272

8.  Structure of the provirus within NIH 3T3 cells transfected with Harvey sarcoma virus DNA.

Authors:  M P Goldfarb; R A Weinberg
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

9.  Rous sarcoma virus variants that carry the cellular src gene instead of the viral src gene cannot transform chicken embryo fibroblasts.

Authors:  H Iba; T Takeya; F R Cross; T Hanafusa; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

10.  Avian myeloblastosis provirus cloned in a lambda bacteriophage is leukemogenic.

Authors:  R F Silva; B Perbal; D G Bergmann; M A Baluda
Journal:  J Virol       Date:  1982-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.